News Releases
Cannabix Makes Significant Breakthrough in FAIMS Technology Development
March 2, 2020
Vancouver, British Columbia, March 2, 2020 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of marijuana breathalyzer devices for law enforcement and the workplace reports that a significant technological development has been achieved with its FAIMS- (field asymmetric waveform ion mobility spectrometry) marijuana breathalyzer prototype. Cannabix scientists have been characterizing the device for several months to increase resolving power and sensitivity. The Company is pleased to report that the Beta 3.1 FAIMS device has achieved ion-resolving levels that enable the isolation of ∆9-tetrahydrocannabinol (“THC”) in human breath and suppress background compounds effectively. With human subject breath testing performed up to 90 minutes after smoking marijuana and nicotine cigarettes, the Cannabix FAIMS device was able to selectively isolate THC or nicotine and supress unwanted background volatile organic compounds. In addition, metabolites for both cannabis and nicotine were detected. Subject testing up to 90 minutes after smoking was accomplished using only a few breath samples from the test subject. The characterization work and recent developments were conducted using a bench version of the Beta 3.1 FAIMS device coupled to mass spectrometer for validation. A number of factors including FAIMS cell geometry, flow optimization and ion-focusing techniques have contributed to this latest development.
“I’m impressed with the progress that has been made by the Cannabix team in the development of this newest version; the sensitivity and selectivity is impressive. I look forward to continued collaborations between UF and Cannabix to advance FAIMS detection.” says Dr. Richard Yost, Cannabix Scientific Advisor.
“We are very excited about our recent results on being able to consistently resolve THC and other analytes from breath. It is hard to overstate the significance of these achievements in atmospheric conditions (without vacuum). These key steps will result in a new type of device that the analytical and diagnostic fields have been seeking for breath analysis.” says Dr. Raj Attariwala, Chief Scientific Officer
Disclaimer:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, Cannabix Technologies Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.
